W. Rathmell
Last active: 4/27/2021

  1. A Pilot Clinical Study in Characterization of Malignant Renal-cell Carcinoma Subtype with Contrast-enhanced Ultrasound. Kasoji SK, Chang EH, Mullin LB, Chong WK, Rathmell WK, Dayton PA (2017) Ultrason Imaging 39(2): 126-136
    › Primary publication · 27659687 (PubMed) · PMC5599099 (PubMed Central)
  2. A Case Report of Severe Type B Lactic Acidosis Following First Dose of Nivolumab in a VHL-Mutated Metastatic Renal Cell Carcinoma. Nakajima E, Leger P, Mayer IA, Neuss MN, Chism DD, Rathmell WK (2017) Kidney Cancer 1(1): 83-88
    › Primary publication · 30334008 (PubMed) · PMC6179105 (PubMed Central)
  3. Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry-Based Phosphotyrosine Proteomics. Haake SM, Li J, Bai Y, Kinose F, Fang B, Welsh EA, Zent R, Dhillon J, Pow-Sang JM, Chen YA, Koomen JM, Rathmell WK, Fishman M, Haura EB (2016) Clin Cancer Res 22(22): 5605-5616
    › Primary publication · 27220961 (PubMed) · PMC5122466 (PubMed Central)
  4. Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups. de Velasco G, Miao D, Voss MH, Hakimi AA, Hsieh JJ, Tannir NM, Tamboli P, Appleman LJ, Rathmell WK, Van Allen EM, Choueiri TK (2016) Cancer Immunol Res 4(10): 820-822
    › Primary publication · 27538576 (PubMed) · PMC5050137 (PubMed Central)
  5. Structure/Function Analysis of Recurrent Mutations in SETD2 Protein Reveals a Critical and Conserved Role for a SET Domain Residue in Maintaining Protein Stability and Histone H3 Lys-36 Trimethylation. Hacker KE, Fahey CC, Shinsky SA, Chiang YJ, DiFiore JV, Jha DK, Vo AH, Shavit JA, Davis IJ, Strahl BD, Rathmell WK (2016) J Biol Chem 291(40): 21283-21295
    › Primary publication · 27528607 (PubMed) · PMC5076534 (PubMed Central)
  6. Patients with ClearCode34-identified molecular subtypes of clear cell renal cell carcinoma represent unique populations with distinct comorbidities. Haake SM, Brooks SA, Welsh E, Fulp WJ, Chen DT, Dhillon J, Haura E, Sexton W, Spiess PE, Pow-Sang J, Rathmell WK, Fishman M (2016) Urol Oncol 34(3): 122.e1-7
    › Primary publication · 26546482 (PubMed) · PMC4761468 (PubMed Central)
  7. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SM, Anjum S, Wang J, Manyam G, Zoppoli P, Ling S, Rao AA, Grifford M, Cherniack AD, Zhang H, Poisson L, Carlotti CG, Tirapelli DP, Rao A, Mikkelsen T, Lau CC, Yung WK, Rabadan R, Huse J, Brat DJ, Lehman NL, Barnholtz-Sloan JS, Zheng S, Hess K, Rao G, Meyerson M, Beroukhim R, Cooper L, Akbani R, Wrensch M, Haussler D, Aldape KD, Laird PW, Gutmann DH, TCGA Research Network, Noushmehr H, Iavarone A, Verhaak RG (2016) Cell 164(3): 550-63
    › Primary publication · 26824661 (PubMed) · PMC4754110 (PubMed Central)
  8. Methylated α-tubulin antibodies recognize a new microtubule modification on mitotic microtubules. Park IY, Chowdhury P, Tripathi DN, Powell RT, Dere R, Terzo EA, Rathmell WK, Walker CL (2016) MAbs 8(8): 1590-1597
    › Primary publication · 27594515 (PubMed) · PMC5098444 (PubMed Central)
  9. Management of Indeterminate Cystic Kidney Lesions: Review of Contrast-enhanced Ultrasound as a Diagnostic Tool. Chang EH, Chong WK, Kasoji SK, Dayton PA, Rathmell WK (2016) Urology : 1-10
    › Primary publication · 26483268 (PubMed) · PMC5500195 (PubMed Central)
  10. Kidney cancer: Rest ASSUREd, much can be learned from adjuvant studies in renal cancer. Chism DD, Rathmell WK (2016) Nat Rev Nephrol 12(6): 317-8
    › Primary publication · 27108841 (PubMed) · PMC4871728 (PubMed Central)